This infographic explores the emerging concepts of disease activity, disease stability, and disease control in COPD.
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga highlights the multidimensional burden of uncontrolled AD and how the various burdens contribute to Cumulative Life Course Impairment (CLCI).

Understand the impact of moderate chronic obstructive pulmonary disease (COPD) exacerbations on future exacerbation risk, lung function decline, mortality, and patient quality of life.

Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airway remodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma.

Dr Kwatra poses the question: How do we assess disease modification in PN, and can treating early stop tissue damage and worsening of systemic diseases associated with PN?

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses how moderate-to-severe AD may hinder growth in pediatric patients and highlights data showing treatment with dupilumab may increase vertical growth in children of lower stature.

In this clip from the April WCPD 2025 symposium, Dr Paula Luna discusses how moderate-to-severe AD may hinder growth in pediatric patients.

Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.